Needham lowered the firm’s price target on OncoCyte to $0.45 from $1.40 and keeps a Buy rating on the shares. The analyst cites the company’s Q4 revenue miss, though the firm also notes that OncoCyte has made significant progress in reducing cash burn from its reprioritization plan and expects further improvement in 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OCX:
- OncoCyte prices $13.9M common stock offering
- OncoCyte Corp (OCX) Q4 Earnings Cheat Sheet
- Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
- OncoCyte to delay filing Annual Report on Form 10-K
- Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
